Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 401–500 of 1,018
DHAKAM, Z., MCENIERY, C., YASMIN, COCKCROFT, J., BROWN, M., & WILKINSON, I. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.08.007 · Cited by 169
Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?
WEIR, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.019 · Cited by 169
Beyond blood pressure: the endothelium and atherosclerosis progression*
Schiffrin, E. L. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)03006-6 · Cited by 168
Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Fonseca, V., Desouza, C., Asnani, S., & Jialal, I. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0034 · Cited by 168
Coronary Heart Disease in Patients With Diabetes
Berry, C., Tardif, J.-C., & Bourassa, M. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.046 · Cited by 168
Arterial Stiffness and Cardiovascular Therapy
Janić, M., Lunder, M., & Šabović, M. (2014) · BioMed Research International · doi:10.1155/2014/621437 · Cited by 168
Gerdts, E., Cramariuc, D., de Simone, G., Wachtell, K., Dahlof, B., & Devereux, R. B. (2008) · European Journal of Echocardiography · doi:10.1093/ejechocard/jen155 · Cited by 167
Self-citationCardiac Mechanics in Mild Hypertensive Heart Disease: A Speckle-Strain Imaging Study
Narayanan, A., Aurigemma, G. P., Chinali, M., Hill, J. C., Meyer, T. E., & Tighe, D. A. (2009) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.108.811620 · Cited by 167
Dawson, J., & Walters, M. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02785.x · Cited by 167
Merlotti, C., Morabito, A., & Pontiroli, A. E. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12270 · Cited by 167
Isolated Systolic Hypertension in the Elderly
Chobanian, A. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp071137 · Cited by 167
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension
Crowley, S. D., Frey, C. W., Gould, S., Griffiths, R., Ruiz, P., Burchette, J. L., Howell, D. N., Makhanova, N., Yan, M., Kim, H., et al. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2007 · Cited by 167
Recent advances involving the renin–angiotensin system
Crowley, S. D., & Coffman, T. M. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.023 · Cited by 167
The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction
Schmaier, A. H. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00535.2002 · Cited by 167
Kingston, R. (2004) · Journal of Hypertension · doi:10.1097/00004872-200410000-00006 · Cited by 166
Kouyama, R., Suganami, T., Nishida, J., Tanaka, M., Toyoda, T., Kiso, M., Chiwata, T., Miyamoto, Y., Yoshimasa, Y., Fukamizu, A., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0003 · Cited by 166
Rationale, design, methods and baseline characteristics of the Asklepios Study
Rietzschel, E.-R., De Buyzere, M. L., Bekaert, S., Segers, P., De Bacquer, D., Cooman, L., Van Damme, P., Cassiman, P., Langlois, M., van Oostveldt, P., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328012c380 · Cited by 166
Kurata, A., Nishizawa, H., Kihara, S., Maeda, N., Sonoda, M., Okada, T., Ohashi, K., Hibuse, T., Fujita, K., Yasui, A., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001810 · Cited by 166
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection
Werner, C., Baumhäkel, M., Teo, K. K., Schmieder, R., Mann, J., Unger, T., Yusuf, S., & Böhm, M. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0668-3 · Cited by 166
Brown, M. J., McInnes, G. T., Papst, C. C., Zhang, J., & MacDonald, T. M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62003-x · Cited by 166
Hirata, K., Vlachopoulos, C., Adji, A., & O'Rourke, M. F. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000160211.56103.48 · Cited by 165
Kaplan, N. M., & Opie, L. H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67965-8 · Cited by 165
Lamb, R. E., & Goldstein, B. J. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01789.x · Cited by 165
Proteinuria and its relation to cardiovascular disease
Delles, C., & Currie, G. E. (2013) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40522 · Cited by 165
Reboldi, G., Angeli, F., Cavallini, C., Gentile, G., Mancia, G., & Verdecchia, P. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328306ebe2 · Cited by 164
Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.933 · Cited by 164
Soliman, E. Z., Ambrosius, W. T., Cushman, W. C., Zhang, Z.-M., Bates, J. T., Neyra, J. A., Carson, T. Y., Tamariz, L. J., Ghazi, L., Cho, M. E., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.028441 · Cited by 163
The DREAM Trial Investigators (2004) · Diabetologia · doi:10.1007/s00125-004-1485-5 · Cited by 163
Andersen, K. K., Weinberger, M. H., Egan, B. M., Constance, C. M., Ali, M. A., Jin, J., & Keefe, D. L. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f3ad9a · Cited by 163
Coronary Heart Disease in Patients With Diabetes
Berry, C., Tardif, J., & Bourassa, M. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.045 · Cited by 164
South African hypertension guideline 2006.
Seedat, Y. K., Ma, C., Milne, F. J., Opie, L. H., Vj, P.-A., Rayner, B. L., & Veriava, Y. (2006) · PubMed · Cited by 162
Julius, S., Weber, M. A., Kjeldsen, S. E., McInnes, G. T., Zanchetti, A., Brunner, H. R., Laragh, J. H., Schork, M. A., Hua, T. A., Amerena, J. V., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000236119.96301.f2 · Cited by 162
Self-citationOparil, S., Melino, M. R., Lee, J., Serrano-Fernandez, V., & Heyrman, R. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.07.008 · Cited by 162
Self-citationLong-term neprilysin inhibition — implications for ARNIs
Campbell, D. J. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.200 · Cited by 163
Circadian Influence on Metabolism and Inflammation in Atherosclerosis
McAlpine, C. S., & Świrski, F. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.308034 · Cited by 161
Effects of β-blockers on glucose and lipid metabolism
Fonseca, V. A. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903533681 · Cited by 160
Kjeldsen, S. E., Julius, S., Mancia, G., McInnes, G. T., Hua, T., Weber, M. A., Coca, A., Ekman, S., Girerd, X., Jamerson, K., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000234122.55895.5b · Cited by 160
Self-citationPetersen, J. L., & McGuire, D. K. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.007 · Cited by 159
The kidney, a cardiovascular risk marker, and a new target for therapy
de Zeeuw, D., Hillege, H. L., & de Jong, P. E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09805.x · Cited by 158
Eplerenone: Cardiovascular Protection
Brown, N. J. (2003) · Circulation · doi:10.1161/01.cir.0000071081.35693.9a · Cited by 158
Andraws, R., & Brown, D. L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.068 · Cited by 158
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655761 · Cited by 158
Mancia, G., Brown, M., Castaigne, A., de Leeuw, P., Palmer, C. R., Rosenthal, T., Wagener, G., & Ruilope, L. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000057420.27692.ad · Cited by 157
Obesity-hypertension: an ongoing pandemic
Francischetti, E. A., & Genelhu, V. A. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01262.x · Cited by 162
Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou, S. S., Mikhailidis, D. P., & Elisaf, M. (2004) · Angiology · doi:10.1177/00033197040550i601 · Cited by 157
Ciulla, M. M., Paliotti, R., Esposito, A., Dìez, J., López, B., Dahlöf, B., Nicholls, M. G., Smith, R. D., Gilles, L., Magrini, F., et al. (2004) · Circulation · doi:10.1161/01.cir.0000137118.47943.5c · Cited by 157
Self-citationThe role of angiotensin II in regulating vascular structural and functional changes in hypertension
Touyz, R. M. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0073-2 · Cited by 157
Oikarinen, L., Nieminen, M. S., Viitasalo, M. T., Toivonen, L. K., Jern, S., Dahlöf, B., Devereux, R. B., & Okin, P. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000125230.46080.c6 · Cited by 156
Self-citationRacial differences in central blood pressure and vascular function in young men
Heffernan, K. S., Jae, S. Y., Wilund, K. R., Woods, J. A., & Fernhall, B. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00902.2008 · Cited by 156
Arterial stiffness and the systolic hypertension syndrome
Izzo, J. L. (2004) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000126581.89648.10 · Cited by 156
Angiotensin II-Induced Signal Transduction Mechanisms for Cardiac Hypertrophy
Bhullar, S. K., & Dhalla, N. S. (2022) · Cells · doi:10.3390/cells11213336 · Cited by 155
Prevention of depression in older age
Almeida, O. P. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.03.005 · Cited by 154
Heart Rate and Blood Pressure: Any Possible Implications for Management of Hypertension?
Reule, S. A., & Drawz, P. E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0306-3 · Cited by 157
Better blood pressure control: how to combine drugs
Mj, B., Cruickshank, J. K., Dominiczak, A. F., MacGregor, G. A., Poulter, N. R., Russell, G. I., Thom, S., & Williams, B. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001511 · Cited by 153
Immunologic Effects of the Renin-Angiotensin System
Crowley, S. D., & Rudemiller, N. P. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101066 · Cited by 153
Review: Stroke prevention: modifying risk factors
Romero, J. R., Morris, J. G., & Pikula, A. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708093847 · Cited by 155
Understanding the Use of Composite Endpoints in Clinical Trials
McCoy, C. E. (2018) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2018.4.38383 · Cited by 152
Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients
Chen, S.-C., & Tseng, C.-H. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.88 · Cited by 152
Vaidya, A., & Williams, J. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.09.007 · Cited by 151
Klein, L., O’Connor, C. M., Gattis, W. A., Zampino, M., Luca, L. D., Vitarelli, A., Fedele, F., & Gheorghiade, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03336-2 · Cited by 151
Regeneration of the Heart in Diabetes by Selective Copper Chelation
Cooper, G. J. S., Phillips, A. R. J., Choong, S. Y., Leonard, B. L., Crossman, D. J., Brunton, D. H., Saafi, ’. L., Dissanayake, A. M., Cowan, B. R., Young, A. A., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2501 · Cited by 151
Infeld, M. M., Wahlberg, K. J., Cicero, J., Plante, T. B., Meagher, S., Novelli, A., Habel, N., Krishnan, A. M., Silverman, D. N., LeWinter, M. M., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.5320 · Cited by 150
A Review of Nebivolol Pharmacology and Clinical Evidence
Fongemie, J., & Felix-Getzik, E. M. (2015) · Drugs · doi:10.1007/s40265-015-0435-5 · Cited by 154
Pharmacological approaches to the prevention of type 2 diabetes mellitus
Majety, P., Orquera, F. A. L., Edem, D., & Hamdy, O. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1118848 · Cited by 152
Pro-inflammatory cytokines in acute coronary syndromes: From bench to bedside
Tousoulis, D., Antoniades, C. A., Koumallos, N., & Stefanadis, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.04.003 · Cited by 149
Backer, G. D., Ambrosio, G., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · PubMed · doi:10.1097/01.hjr.0000087913.96265.e2 · Cited by 149
Gerdts, E., Okin, P. M., de Simone, G., Cramariuc, D., Wachtell, K., Boman, K., & Devereux, R. B. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.107474 · Cited by 149
Self-citationObesity Associated Hypertension: New Insights into Mechanism
Kang, Y. S. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.2.46 · Cited by 148
Kotchen, T. A. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.177766 · Cited by 147
The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications
COOPER, M. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.004 · Cited by 147
Julius, S., Kjeldsen, S. E., & Weber, M. A. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.08.044 · Cited by 147
Self-citationNovel RAAS agonists and antagonists: clinical applications and controversies
Romero, C. A., Orias, M., & Weir, M. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.6 · Cited by 147
Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers
Schmieder, R. E. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.11.032 · Cited by 147
Resistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005
Marín, R., de la Sierra, Á., Armario, P., Campo, C., Banegas, J. R., & Gorostidi, M. (2005) · Medicina Clínica · doi:10.1157/13076402 · Cited by 152
Lind, L., Ärnlöv, J., Lindahl, B., Siegbahn, A., Sundström, J., & Ingelsson, E. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.023 · Cited by 145
Coelho‐Filho, O. R., Shah, R. V., Mitchell, R. N., Neilan, T. G., Moreno, H., Simonson, B., Kwong, R. K., Rosenzweig, A., Das, S., & Jerosch‐Herold, M. (2013) · Circulation · doi:10.1161/circulationaha.112.000438 · Cited by 146
Combination Therapy in Hypertension
Gradman, A. H., Basile, J. N., Carter, B. L., Bakris, G. L., & on behalf of the American Society of Hypertension Writing Group (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00397.x · Cited by 145
Gaciong, Z. A., Siński, M., & Lewandowski, J. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0401-0 · Cited by 144
Jamerson, K., Bakris, G. L., Wun, C. C., Dahlöf, B., Lefkowitz, M. P., Manfreda, S., Pitt, B., Velazquez, E. J., & Weber, M. A. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.05.004 · Cited by 144
Self-citationHypertension in Metabolic Syndrome: Novel Insights
Katsimardou, A., Imprialos, K. P., Stavropoulos, K., Sachinidis, A. G., Doumas, M. N., & Athyros, V. G. (2019) · Current Hypertension Reviews · doi:10.2174/1573402115666190415161813 · Cited by 144
Okin, P. M., Devereux, R. B., Nieminen, M. S., Jern, S., Oikarinen, L., Viitasalo, M. T., Toivonen, L. K., Kjeldsen, S. E., Julius, S., Snapinn, S. M., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000132556.91792.6a · Cited by 144
Self-citationLeft ventricular hypertrophy as a predictor of cardiovascular risk
Gosse, P. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000165625.79933.9a · Cited by 143
Valsartan Improves Arterial Stiffness in Type 2 Diabetes Independently of Blood Pressure Lowering
Karalliedde, J., Smith, A., DeAngelis, L., Mirenda, V., Kandra, A., Botha, J., Ferber, P., & Viberti, G. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.111674 · Cited by 143
Chrysant, S. G., Weber, M. A., Wang, A. C., & Hinman, D. J. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.11.003 · Cited by 143
Hypertension and Stroke: Epidemiological Aspects and Clinical Evaluation
Pistoia, F., Sacco, S., Degan, D., Tiseo, C., Ornello, R., & Carolei, A. (2015) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-015-0115-2 · Cited by 147
Reboussin, D. M., Allen, N. B., Griswold, M. E., Guallar, E., Hong, Y., Lackland, D. T., Miller, E. (. R., Polonsky, T., Thompson-Paul, A. M., & Vupputuri, S. (2018) · Circulation · doi:10.1161/cir.0000000000000601 · Cited by 142
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.933 · Cited by 142
Changing Relationship of Blood Pressure with Mortality over Time among Hemodialysis Patients
Stidley, C. A., Hunt, W. C., Tentori, F., Schmidt, D. W., Rohrscheib, M. R., Paine, S., Bedrick, E. J., Meyer, K. B., Johnson, H., & Zager, P. G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110921 · Cited by 142
Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario
Mohan, V., Venkatraman, J. V., & Pradeepa, R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400121 · Cited by 142
Vascular and cardiac benefits of angiotensin receptor blockers
Schiffrin, E. L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01241-x · Cited by 142
I Diretriz Latino-Americana para avaliação e conduta na insuficiência cardíaca descompensada
Bocchi, E. A., Vilas‐Boas, F., Perrone, S. V., Caamaño, A. G., Clausell, N., Moreira, M. D. C. V., Thierer, J. M., Grancelli, H., Junior, C. V. S., de Albuquerque, D. C., et al. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005002200001 · Cited by 142
Mohan, V., Sreedharan, S., Deepa, M., Gokulakrishnan, K., Datta, M., & Deepa, R. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00612.x · Cited by 141
Composite End Points in Clinical Research: A Time for Reappraisal
Armstrong, P. W., & Westerhout, C. M. (2017) · Circulation · doi:10.1161/circulationaha.117.026229 · Cited by 141
Multiplicity Considerations in Clinical Trials
Dmitrienko, A., & D’Agostino, R. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1709701 · Cited by 140
Impaired endothelial function of the retinal vasculature in hypertensive patients
Delles, C., Michelson, G., Harazny, J., Oehmer, S., Hilgers, K. F., & Schmieder, R. E. (2004) · Stroke · doi:10.1161/01.str.0000126597.11534.3b · Cited by 140
Eriksson, J. W., Jansson, P.-A., Carlberg, B., Hägg, A., Kurland, L., Svensson, M. K., Ahlström, H., Ström, C., Lönn, L., Öjbrandt, K., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.119404 · Cited by 140
Beta-blockers for hypertension
Wiysonge, C. S. U., Bradley, H. A., Mayosi, B. M., Maroney, R. T., Mbewu, A., Opie, L., & Volmink, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub2 · Cited by 140
Heart rate, lifespan, and mortality risk
Zhang, G. Q., & Zhang, W. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2008.10.001 · Cited by 139
Cardiovascular risk associated with the metabolic syndrome
Lindsay, R. S., & Howard, B. V. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0013-9 · Cited by 140
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.